Levis MJ - Search Results

1

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ. Perl AE, et al. Among authors: levis mj. Blood. 2022 Jun 9;139(23):3366-3375. doi: 10.1182/blood.2021011583. Blood. 2022. PMID: 35081255 Free PMC article. Clinical Trial.

2

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.

Levis M, Tse KF, Smith BD, Garrett E, Small D. Levis M, et al. Blood. 2001 Aug 1;98(3):885-7. doi: 10.1182/blood.v98.3.885. Blood. 2001. PMID: 11468194 Free article.

3

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D. Levis M, et al. Blood. 2002 Jun 1;99(11):3885-91. doi: 10.1182/blood.v99.11.3885. Blood. 2002. PMID: 12010785 Free article.

4

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Tse KF, et al. Leukemia. 2002 Oct;16(10):2027-36. doi: 10.1038/sj.leu.2402674. Leukemia. 2002. PMID: 12357354

5

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.

Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, Small D. Zheng R, et al. Blood. 2004 Jan 1;103(1):267-74. doi: 10.1182/blood-2003-06-1969. Epub 2003 Sep 11. Blood. 2004. PMID: 12969963 Free article.

6

FLT3: ITDoes matter in leukemia.

Levis M, Small D. Levis M, et al. Leukemia. 2003 Sep;17(9):1738-52. doi: 10.1038/sj.leu.2403099. Leukemia. 2003. PMID: 12970773 Review.

7

Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression.

Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. Zheng R, et al. Blood. 2004 Mar 1;103(5):1883-90. doi: 10.1182/blood-2003-06-1978. Epub 2003 Oct 30. Blood. 2004. PMID: 14592841 Free article.

8

Novel FLT3 tyrosine kinase inhibitors.

Levis M, Small D. Levis M, et al. Expert Opin Investig Drugs. 2003 Dec;12(12):1951-62. doi: 10.1517/13543784.12.12.1951. Expert Opin Investig Drugs. 2003. PMID: 14640939 Review.

9

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Smith BD, et al. Blood. 2004 May 15;103(10):3669-76. doi: 10.1182/blood-2003-11-3775. Epub 2004 Jan 15. Blood. 2004. PMID: 14726387 Free article. Clinical Trial.

10

Small molecule FLT3 tyrosine kinase inhibitors.

Levis M, Small D. Levis M, et al. Curr Pharm Des. 2004;10(11):1183-93. doi: 10.2174/1381612043452604. Curr Pharm Des. 2004. PMID: 15078134 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

221 results

Search Page